ISRCTN94465371Completed未知

PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV-negative gay men

Medical Research Council Clinical Trials Unit (MRC CTU) (UK)0 sites500 target enrollmentStarted: February 28, 2013Last updated: January 6, 2020

Conditions

Trial Snapshot

•1. Born to male gender, age 18 years or more
•2. Previously attended the enrolling clinic on at least one occasion
•3. Completed a screen for HIV and sexually transmitted infections (STIs)
•4. HIV negative by a routinely used assay within 4 weeks prior to or on the day of randomisation
•5. Reported unprotected anal intercourse (UAI) on more than one occasion within the 90 days prior to randomisation
•6. Likely, in the opinion of the volunteer, to have UAI in the next 90 days
•7. Willing and able to comply with the visit schedule throughout the follow-up period
•8. Willing and able to provide written informed consent

•1. An acute viral illness that could be due to HIV seroconversion
•2. Any contraindications to Truvada according to the current package insert
•3. Treatment for hepatitis B infection indicated or ongoing
•4. Unlikely, in the opinion of the clinician, to comply with the randomised allocation

Sponsor

Medical Research Council Clinical Trials Unit (MRC CTU) (UK)